Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe-Reference-Cited by-同舟云学术

Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

Published:2018-02 Issue:5 Volume:19 Page:324-338
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Santos JR¹^ORCID,Cozzi‐Lepri A²,Phillips A²,De Wit S³,Pedersen C⁴,Reiss P⁵,Blaxhult A⁶,Lazzarin A⁷,Sluzhynska M⁸,Orkin C⁹,Duvivier C¹⁰,Bogner J¹¹,Gargalianos‐Kakolyris P¹²,Schmid P¹³,Hassoun G¹⁴,Khromova I¹⁵,Beniowski M¹⁶,Hadziosmanovic V¹⁷,Sedlacek D¹⁸,Paredes R¹¹⁹²⁰,Lundgren JD²¹,Losso M,Kundro M,Schmied B,Zangerle R,Karpov I,Vassilenko A,Mitsura V. M,Paduto D,Clumeck N,Delforge M,Florence E,Vandekerckhove L,Begovac J,Machala L,Jilich D,Kronborg G,Benfield T,Gerstoft J,Katzenstein T,Møller N. F,Ostergaard L,Wiese L,Nielsen L. N,Zilmer K,Smidt J,Ristola M,Aho I,Viard J.‐P,Girard P.‐M,Pradier C,Fontas E,Rockstroh J,Schmidt R,Degen O,Stellbrink H. J,Stefan C,Fätkenheuer G,Chkhartishvili N,Gargalianos P,Xylomenos G,Lourida P,Sambatakou H,Szlávik J,Gottfredsson M,Mulcahy F,Yust I,Turner D,Burke M,Shahar E,Elinav H,Haouzi M,Elbirt D,Sthoeger Z. M,D'Arminio Monforte A,Esposito R,Mazeu I,Mussini C,Mazzotta F,Gabbuti A,Vullo V,Lichtner M,Zaccarelli M,Antinori A,Acinapura R,Plazzi M,Castagna A,Gianotti N,Galli M,Ridolfo A,Rozentale B,Uzdaviniene V,Matulionyte R,Staub T,Hemmer R,Ormaasen V,Maeland A,Bruun J,Knysz B,Gasiorowski J,Inglot M,Horban A,Bakowska E,Flisiak R,Grzeszczuk A,Parczewski M,Pynka M,Maciejewska K,Mularska E,Smiatacz T,Gensing M,Jablonowska E,Malolepsza E,Wojcik K,Mozer‐Lisewska I,Caldeira L,Mansinho K,Maltez F,Radoi R,Panteleev A,Panteleev O,Yakovlev A,Trofimora T,Kuzovatova E,Borodulina E,Vdoushkina E,Jevtovic D,Tomazic J,Gatell J. M,Miró J. M,Moreno S,Rodriguez J. M,Clotet B,Jou A,Tural C,Puig J,Bravo I,Domingo P,Gutierrez M,Mateo G,Sambeat M. A,Laporte J. M,Falconer K,Thalme A,Sonnerborg A,Flamholc L,Scherrer A,Weber R,Cavassini M,Calmy A,Furrer H,Battegay M,Kuznetsova A,Kyselyova G,Gazzard B,Johnson A. M,Simons E,Edwards S,Johnson M. A,Mocroft A,Weber J,Scullard G,Clarke A,Leen C,Gatell J,Ledergerber B,Lundgren J,Kirk O,Peters L,Matthews C,Fischer A. H,Bojesen A,Raben D,Kristensen D,Grønborg Laut K,Larsen J. F,Podlekareva D,Shepherd L,Schultze A,Thiebaut R,Burger D,

Affiliation:

1. Fight Against AIDS Foundation Germans Trias i Pujol University Hospital Barcelona Spain

2. Royal Free and University College London UK

3. Centre Hospitalier Universitaire Saint‐Pierre Brussels Belgium

4. Odense University Hospital Odense Denmark

5. Academic Medical Center Amsterdam the Netherlands

6. Karolinska Institute Venhälsan Stockholm Sweden

7. San Raffaele Scientific Institute Milan Italy

8. Lviv Regional HIV/AIDS Prevention and Control Centre Kiev Ukraine

9. Royal London Hospital London UK

10. Hôpital Necker‐Enfants Malades Paris France

11. Medizinische Poliklinik Munchen Germany

12. The General Hospital of Athens “G. Gennimatas” Athens Greece

13. Cantonal Hospital St. Gallen St. Gallen Switzerland

14. Rambam Health Care Campus Haifa Israel

15. Centre for HIV/AIDS and Infectious Diseases Moscow Russia

16. Szpital Specjalistyczny Chorzow Poland

17. Klinicki Centar Univerziteta Sarajevo (KCUS) Sarajevo Bosnia & Herzegovina

18. Charles University Hospital Plzen Czech Republic

19. IrsiCaixa AIDS Research Institute Barcelona Spain

20. Universitat de Vic‐Universitat Central de Catalunya Barcelona Spain

21. Rigshospitalet and University of Copenhagen Copenhagen Denmark

Funder

European Commission

Sixth Framework Programme

Seventh Framework Programme

Pfizer

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.12581

Reference40 articles.

1. World Health Organisation.Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What's new?2015; (November):1–16.

2. European AIDS Clinical Society (EACS).EACS Guidelines. Vol. October.2016. Version 8.1.

3. DHHS Panel on Antiretroviral Guidelines for Adults and adolescents.Guidelines for the Use of Antiretroviral Agents in HIV‐1‐Infected Adults and Adolescents. Department of Health and Human Services. Available athttp://aidsinfo.nih.gov/guidelines(accessed 20 January 2017).

4. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

5. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 Southern African HIV Clinicians Society Adult Antiretroviral Therapy Guidelines: What’s new?;Southern African Journal of HIV Medicine;2023-09-29

2. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial;The Lancet HIV;2022-06

3. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV;PLOS ONE;2021-04-08

4. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch;Biomolecules;2021-03-24

5. High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study;Infection;2020-05-11